Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Revisit Every OncLive On Air Episode From June 2025

July 1st 2025

Read a recap of the episodes of OncLive On Air that debuted in June 2025.

BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD

June 26th 2025

Chandler Park, MD and Midhun Malla, MD discuss treatment personalization in mCRC, with a focus on BRAF V600E–mutant tumors and HER2-altered disease.

ASCO 2025 Plenary: SERENA-6

June 24th 2025

Drs Armstrong and Tawagi discuss key efficacy, safety, and patient-reported outcomes from the phase 3 SERENA-6 study.

Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD

May 29th 2025

Park and Malla discuss evolving approaches to colorectal cancer (CRC) management, with a focus on ctDNA, adjuvant therapy decision-making, and molecular profiling in metastatic disease.

Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD

May 26th 2025

Drs Park and Hanona discuss the ways that public health content creation offers practical advice about a variety of topics but may also spark debate.

Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD

April 21st 2025

In this episode, Drs Park and Hanona give advice to up-and-coming oncology content creators.

Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD

April 16th 2025

Drs Park and Hanona discuss the role of social media in educating patients and oncologists about treatment advances and novel cancer screening methods.

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

April 14th 2025

Drs Park and Koshkin explore the clinical implications of the phase 3 NIAGARA trial for patients with resectable bladder cancer.

FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD

March 13th 2025

Nataliya Uboha, MD, PhD, discusses the FDA approval of first-line tislelizumab-jsgr with platinum-containing chemotherapy for unresectable or metastatic ESCC.

Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc

March 10th 2025

Virginia Kaklamani, MD, DSc, discusses the mechanism of action of inavolisib and the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm.

FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD

March 6th 2025

Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary collaboration will play in integrating this therapy into clinical practice.

FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD

March 3rd 2025

Marwan G. Fakih, MD discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial, and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.

FDA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD

February 20th 2025

Christopher L. Moertel, MD, discusses the significance of the FDA approval of mirdametinib, based on efficacy and safety data from the phase 2 ReNeu trial.

FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

February 13th 2025

Dr Bardia discusses the significance of the FDA approval of Dato-DXd, and pivotal findings from the phase 3 TROPION-Breast01 trial that led to the approval.

How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD

January 28th 2025

Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

December 24th 2024

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD

December 23rd 2024

Dr Moreau highlights key findings on MRD negativity dynamics from IMROZ and their future implications for patients with newly diagnosed multiple myeloma.

Designing Trials and Fueling Collaboration in Oncology: With D. Ross Camidge, MD, PhD; and Mary Redman, PhD

December 18th 2024

Drs Camidge and Redman discuss Dr Redman's role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.

Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD

December 18th 2024

Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.

Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS

December 16th 2024

Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER+/HER2- metastatic breast cancer.